The selection of these gastrointestinal tumor entities is furthermore based on availability of promising preclinical efficacy data of ITPP and other anti-hypoxic agents such as evofosfamide obtained with murine colorectal40–42, hepatoma43 and pancreatic39 cancer cell lines and confinement to one anatomical region amenable to reliable radiological tumor assessment. This evidence concerns the gene TPP1 and cancer.